NeoRx gets research grant from NCI

By AuntMinnie.com staff writers

February 21, 2000 --

Pharmaceutical firm NeoRx has received a small business innovative research (SBIR) grant from the National Cancer Institute to help bring the Seattle-based firm's Pretarget therapy radiopharmaceutical to clinical trials. The grant could be for as much as $950,000 to support testing of the agent, which is targeted at non-Hodgkin's lymphoma.

With Pretarget, the antibody and radionuclide are separately injected and subsequently joined at the tumor. Since the radionuclide is a small, drug-sized molecule, its circulation time is short, thus averting patient exposure to large amounts of radiation that are not targeted directly at the tumor, according to NeoRx.

By AuntMinnie.com staff writers
February 21, 2000

Copyright © 2000 AuntMinnie.com

 

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: